Jiake Ying
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiake Ying has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Fang Lu
Institute of Clinical Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication Guida Li
Feixian People’s Hospital
1 shared publicationHongxian Wu
Zhongshan Hospital
1 shared publicationLulu Zhang
Liaocheng People’s Hospital
1 shared publication- Mengjie Zhao
Department of General Internal Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication Mengli Xiao
NMPA Key Laboratory for Clinical Research and Evaluation of Traditional Chinese Medicine
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 3179489
Efficacy of Fufang E’jiao Jiang in the Treatment of Patients with Qi and Blood Deficiency Syndrome: A Real‐World Prospective Multicenter Study with a Patient Registry
Objective. This nationwide, multicenter prospective observational study with a patient registry was designed to evaluate the efficacy of Fufang E’jiao Jiang (FEJ) in Chinese patients with Qi and blood deficiency syndrome (QBDS). Methods. QBDS patients were consecutively recruited from 81 investigational sites in China from July, 2019, to December, 2020. Patients who met the eligibility criteria were enrolled in a prospective registry database. Baseline characteristics and changes in scores on the traditional Chinese medicine (TCM) symptom evaluation scale for Qi and blood deficiency, the clinical global impression (CGI) scale, the fatigue scale‐14 (FS‐14), and the Pittsburgh sleep quality index (PSQI) were analyzed to determine the clinical efficacy of FEJ. Results. A total of 3,203 patients were recruited. The average remission rate (i.e., the sum of the cure rate and improvement rate) of the 20 symptoms of QBDS was 92.49% after 4 weeks of FEJ treatment, which was higher than at baseline; the rate increased to 94.69% at 8 weeks. The CGI scale revealed that the number of total remissions at 4 and 8 weeks was 3,120 (97.41%) and 415 (100%), respectively. The total FS‐14 scores decreased by 1.67 ± 4.11 (p < 0.001) at 4 weeks and 1.72 ± 3.09 (p < 0.001) at 8 weeks of treatment. The PSQI scores were 6.6 ± 4.7 and 6.52 ± 3.07 at 4 and 8 weeks, respectively, which were significantly lower than the baseline scores (p < 0.001; p = 0.0033). Both the subhealth fatigue (SF) and iron deficiency anemia (IDA) groups showed significantly improved clinical symptoms of QBDS (p < 0.01). Between‐group comparisons revealed significantly greater improvements in FS‐14 and PSQI scores in the SF group than in the IDA group (p < 0.05). A multivariate logistic regression analysis showed that disease course, FS‐14 score at baseline, and four‐week FEJ doses were independent risk factors for the degree of symptom relief in QBDS patients (p < 0.05). Conclusion. In real‐world settings, FEJ has a promising effect in treating QBDS and can significantly improve the severity of its symptoms.
- 1 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 3179489
Open AccessEfficacy of Fufang E’jiao Jiang in the Treatment of Patients with Qi and Blood Deficiency Syndrome: A Real‐World Prospective Multicenter Study with a Patient Registry
Objective. This nationwide, multicenter prospective observational study with a patient registry was designed to evaluate the efficacy of Fufang E’jiao Jiang (FEJ) in Chinese patients with Qi and blood deficiency syndrome (QBDS). Methods. QBDS patients were consecutively recruited from 81 investigational sites in China from July, 2019, to December, 2020. Patients who met the eligibility criteria were enrolled in a prospective registry database. Baseline characteristics and changes in scores on the traditional Chinese medicine (TCM) symptom evaluation scale for Qi and blood deficiency, the clinical global impression (CGI) scale, the fatigue scale‐14 (FS‐14), and the Pittsburgh sleep quality index (PSQI) were analyzed to determine the clinical efficacy of FEJ. Results. A total of 3,203 patients were recruited. The average remission rate (i.e., the sum of the cure rate and improvement rate) of the 20 symptoms of QBDS was 92.49% after 4 weeks of FEJ treatment, which was higher than at baseline; the rate increased to 94.69% at 8 weeks. The CGI scale revealed that the number of total remissions at 4 and 8 weeks was 3,120 (97.41%) and 415 (100%), respectively. The total FS‐14 scores decreased by 1.67 ± 4.11 (p < 0.001) at 4 weeks and 1.72 ± 3.09 (p < 0.001) at 8 weeks of treatment. The PSQI scores were 6.6 ± 4.7 and 6.52 ± 3.07 at 4 and 8 weeks, respectively, which were significantly lower than the baseline scores (p < 0.001; p = 0.0033). Both the subhealth fatigue (SF) and iron deficiency anemia (IDA) groups showed significantly improved clinical symptoms of QBDS (p < 0.01). Between‐group comparisons revealed significantly greater improvements in FS‐14 and PSQI scores in the SF group than in the IDA group (p < 0.05). A multivariate logistic regression analysis showed that disease course, FS‐14 score at baseline, and four‐week FEJ doses were independent risk factors for the degree of symptom relief in QBDS patients (p < 0.05). Conclusion. In real‐world settings, FEJ has a promising effect in treating QBDS and can significantly improve the severity of its symptoms.